HC Wainwright Reaffirms “Buy” Rating for BiomX (NYSEMKT:PHGE)

BiomX (NYSEMKT:PHGE)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $21.00 target price on the stock. HC Wainwright also issued estimates for BiomX’s Q1 2025 earnings at ($0.42) EPS, Q2 2025 earnings at ($0.46) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.53) EPS, FY2025 earnings at ($1.90) EPS, FY2026 earnings at ($1.86) EPS, FY2027 earnings at ($2.08) EPS and FY2028 earnings at ($1.84) EPS.

BiomX Stock Performance

Shares of NYSEMKT:PHGE opened at $0.59 on Friday. The company’s 50 day simple moving average is $0.71 and its 200 day simple moving average is $0.75. The company has a debt-to-equity ratio of 0.51, a current ratio of 2.84 and a quick ratio of 2.84. BiomX has a 1 year low of $0.48 and a 1 year high of $4.99. The stock has a market capitalization of $14.65 million, a price-to-earnings ratio of -0.78 and a beta of 1.38.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in PHGE. JPMorgan Chase & Co. acquired a new stake in shares of BiomX during the 4th quarter valued at $314,000. Allostery Investments LP bought a new position in BiomX in the fourth quarter valued at about $470,000. Finally, Alyeska Investment Group L.P. acquired a new stake in shares of BiomX during the fourth quarter valued at about $632,000. Institutional investors own 40.57% of the company’s stock.

About BiomX

BiomX Inc, a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis.